Sales in pharmaceuticals products in India has come down sharply in July to less than half of the figures registered in the previous month.
Sales in pharmaceuticals grew only 8.9 percent to 3,456.41 Crores for month of July compared to 18.3% growth in the month of Jun’09, according to a survey report based on the secondary sales audit by ORG IMS, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries.
After registering a blistering 18.3% growth in the month of Jun’09, the pharmaceutical retail market was relatively subdued in July 09, posting a modest growth of 8.9%. However, on an overall basis the market remains in line with previous year’s trend.
Most parts of India sufffered a shortfall of yearly monsoon this season leading to a fall in retails sales of anti-infectives, cough & cold preparations, anti-diarrheals, anti-asthmatics & anti-inflammatory drugs.
The monsoon shortfall in most parts of India in July appears to be the likely contributor to this dip in growth, with categories like anti-infectives, cough & cold preparations, anti-diarrheals, anti-asthmatics & anti-inflammatory/anti-rheumatics (which normally show a seasonal spurt in the month of July) posting low to declining growths, noted the report.
The rankings of the top 25 companies in month of July ’09 have also undergone significant changes in the month of July compared to June’09.
Alembic has gained two ranks and has moved up to rank 18. Novartis, Macleod’s Pharma have gained one rank each and have moved up to rank 21 and 22 .
However, there was no change in the rankings of top 5 companies -Cipla, Ranbaxy, GSK, Piramal Healthcare & Sun. Mankind Pharma jumped 1 rank up to secure the 8th position from the previous 9th position.
Among the top 10 products, Novartis anti-inflammatory pain relieving drug Voveran has maintained its top position in the month of July’09, as compared to the month Jun’09. Oral cephalosporin antibiotic Zifi from Mumbai-based FDC Ltd has leaped 5 ranks & moved up to rank 8. Revital, a vitamins and mineral supplement from Ranbaxy, has gained 2 ranks and moved up to rank 7, whereas antibiotics Taxim (Alkem) and Augmentin (GSK) have gained one rank each and moved up to rank 6 and 9 respectively.
Other top gainers include, azithromycin antibiotic Azithral from United pharmacies which leaped 5 ranks and moved up to rank 17.Calpol (paracetamol/acetaminiphen) leaped 3 ranks, Ranbaxy’s anti-hypertensive Storvas leaped 2 ranks and Aciloc (anti-acidity) leaped 6 ranks to move up to rank 14,18 and 22 respectively. Anti-infective Sporidex has gained 5 ranks and moved up to rank 25.